AzTrials
AzTrials

Treatment-resistant DepressionPhase 2EPIsoDENCT04670081

Efficacy and Safety of Psilocybin in Treatment-Resistant Major Depression

A Phase 2 study testing Psilocybin and Nicotinamide in people with Treatment-resistant Depression, run by Central Institute of Mental Health, Mannheim at 2 sites in Germany.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

The study aims to investigate the safety and efficacy of oral psilocybin administered under supportive conditions in treatment-resistant major depression (TRD). The study is a bi-centric, prospective, randomized, active placebo-controlled study investigating the effects of 25 mg and 5 mg (p.o.) psilocybin versus… Read more about this study

Who is it for?
Ages 25 to 65 years
Conditions the study is for
Treatment-resistant Depression
What is being tested?
Psilocybin and Nicotinamide
Could I receive a placebo?
Yes, some participants may receive a placebo
How many people
144 participants
Where
2 sitesGermany
Study dates
10 Jun 2021to 11 Dec 2024
Phase
Phase 2
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 25 to 65 years
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • 25 to 65 years of age
  • Diagnosis of major depressive disorder (single and recurrent episodes) of moderate to severe degree (HAM-D score ≥ 17) according to the Diagnostic and Statistical Manual of Mental Disorders (DSM-5) without psychotic features. Included ICD-10 diagnoses are ICD-10: F32.1, F32.2, F33.1, F33.2.
  • If single episode, duration must be ≥ 3 months.
  • Patients must meet criteria for treatment-resistance, defined as
  • no adequate improvement despite two adequate courses of antidepressant treatment (6 weeks each, minimum) with drugs of different pharmacological classes in the current depressive episode. Augmentation with an add-on treatment counts as a second treatment.
  • Patients have discontinued any monoaminergic psychiatric medication (i.e. SRIs, antipsychotic medication) for at least 2 weeks before the first dosing session.
Show all 12Show fewer
  • Patients who are still on any monoaminergic psychiatric medication at screening must agree to down-titrate over an individualized down-titration schedule (minimum 2 weeks; if they have been taken Fluoxetine the down-titration phase should be minimum 5 weeks) in close supervision by their out-patient psychiatrist and the study team. The treating psychiatrist must agree to supervise and monitor the down-titration and to collaborate with the study team by signing a "treatment agreement form".
  • If the treating psychiatrist refuses to monitor the down-titration, the patient has to agree to down-titrate under supervision of clinicians in the outpatient clinics of the two study sites or trial physicians and to come in for weekly monitoring visits.
  • The subjects are abstinent from alcohol (breathalyzer blood alcohol concentration (BAC) level 0.00) and a negative urine drug screen at days of dosing
  • The subject must be medically stable based on clinical laboratory tests, medical history, vital signs, and 12-lead ECG performed at screening. If the results of the serum chemistry panel, hematology, or urinalysis are outside the normal reference ranges, retesting of an abnormal lab value(s) that may lead to exclusion will be allowed once during the screening phase. In 12-lead ECG, QTcF should be ≤ 450 ms for males or ≤ 470 ms for females and PR-interval < 220 ms at screening. A retest of an abnormal ECG value will be allowed once in the screening phase. Blood pressure will be the average of 2 measurements. The subject may be included only if the investigator judges the abnormalities or deviations from normal to be not clinically significant or to be appropriate and reasonable for the population under study. This determination must be recorded in the subject's source documents and initialed by the investigator.
  • The subject must be willing and able to adhere to the prohibitions and restrictions specified in this protocol.
  • The subject must sign an informed consent form indicating that he/she understands the purpose of and procedures required for the study including peripheral biomarker monitoring (i.e. blood) and is willing to participate in the study.

Who cannot join

  • Currently comorbid or previously diagnosed DSM-5 diagnosis of a
  • major depressive episode with psychotic features/major depressive disorder with psychotic features (ICD-10: F32.3)
  • schizophrenia spectrum and other psychotic disorders, including schizotypal (personality) disorders, delusional disorder, brief psychotic disorder, schizophreniform disorder, schizoaffective disorder, substance/medication-induced psychotic disorder and psychotic disorder due to another medical condition (ICD-10: F20 - F29)
  • bipolar and related disorders (ICD-10: F30/F31)
  • cluster A personality disorders (paranoid personality disorder, schizoid personality disorder, schizotypal personality disorder) and/or borderline personality disorder (Patients will be carefully screened for presence of those personality disorders by using the SCID-5-PD)
  • Post-traumatic stress disorder (PTSD; ICD-10: F43.1)
Show all 26Show fewer
  • A family history (first-degree relative) of psychosis and/or bipolar disorder
  • The subject has a current or recent history of clinically significant suicidal ideation within the past 6 months, corresponding to a score of 4 (active suicidal ideation with some intent to act, without specific plan) or 5 (active suicidal ideation with specific plan and intent) for ideation on the C-SSRS, or a history of suicidal behavior within the past 1 year, as validated by the C-SSRS at screening. Subjects with a prior suicide attempt of any sort, or prior serious suicidal ideation/plan > 6 months ago, should be carefully screened for current suicidal ideation and only included at the discretion of the investigator.
  • Current comorbid psychiatric diagnosis except their major diagnosis (inclusion criterion 3) in form of
  • Diagnoses mentioned under exclusion criterion 1) b. Substance use disorder (except tobacco-related disorders/caffeine-related disorders) i. Alcohol consumption must be limited to ≤ 40 gram for men and ≤ 20 gram for women per day, e.g. ≤ two/one large beer (0.5 l) for men/women.
  • Use of classical psychedelics (i.e. LSD, psilocybin, mescaline, dimethyltryptamine) in the past year and or more than five life-time uses of classical psychedelics.
  • Failure to establish sufficient rapport with the two therapists as judged by them after the first two preparation sessions
  • Lithium intake
  • The patient has any disorder for which the treatment takes priority over treatment of depression or is likely to interfere with the study treatment or impair treatment compliance. This includes current signs/symptoms of liver or renal insufficiency, hypothyroidism or hyperthyroidism (subjects who are on stable treatment with thyroid supplementation and show an euthyroid metabolism with normal thyroid-stimulating hormone [TSH] may participate), significant cardiac disease (including current or past history of atrial fibrillation/flutter), vascular, pulmonary, endocrine, neurologic (including epilepsy), hematologic, inflammatory (e.g., rheumatoid arthritis, inflammatory bowel disease, Crohn's disease) or metabolic diseases as long as these diseases are not medically controlled or might significantly interfere with participation in the study. Diabetes mellitus (DM) may be allowed when blood glucose is stably controlled (HbA1c less than 7.5% or 58 mmol/mol).
  • To rule out the presence of any serious neurological condition that might be underlying the depression (e.g. Parkinson's Disease, dementia), patients must provide a recent (i.e. not older than 5 years) brain neuroimaging (MRI or CT). If the clinical manifestation has changed qualitatively or in severity, a more recent neuroimaging is required.
  • Women who are pregnant, nursing or refuse to use an effective method of contraception (hormonal or barrier method of birth control; abstinence) throughout their study participation. Women of childbearing potential must have a negative urine pregnancy test at screening and the two dosing days.
  • Positive urine drug screen for any illicit drugs of abuse or alcohol at any of the two dosing days. The regular drug screen includes cocaine, amphetamine, opiates, ecstasy, EDDP, cannabinoids, benzodiazepines and barbiturates.
  • The subject has a QTc interval > 450 ms (for men) or > 470 ms (for women) (Fridericia's correction) at screening or at baseline, as calculated by the ECG equipment and evaluated by the investigator.
  • The subject has received an investigational drug or used an invasive investigational medical device within 3 months before the first administration of the study drug or anticipates participation in another clinical trial until the primary endpoint.
  • The subject is unwilling or unable to undergo multiple venipunctures because of poor tolerability or lack of easy access.
  • The subject is unable to read and understand the patient information and the consent form, complete study-related procedures, and/or communicate with the study staff. Cognitive impairment that would render the informed consent invalid or limit the ability of the subject to comply with the study requirements also excludes from participation in the study.
  • The subject has any condition for which, in the opinion of the investigator, participation would not be in the best interest of the subject (e.g., compromise the well-being) or that could prevent, limit, or confound the protocol-specified assessments.
  • Subject has had major surgery (e.g., requiring general anesthesia) within 12 weeks before screening, or will not have fully recovered from surgery, or has surgery planned during the time the subject is expected to participate in the study.
  • The subject has undergone electroconvulsive therapy (ECT) within twelve months prior to screening or treatment with ketamine or esketamine within six months prior to screening.
  • The subject has received any prior treatment with vagal nerve stimulation, or a deep brain stimulation device.
  • Subject is an employee of the investigator or study site, with direct involvement in the proposed study or other studies under the direction of that investigator or study site, as well as family members of the employees or the investigator.

Trial locations and contacts

2 sites in 1 country.

Germany2 sites

  • Charité Berlin, Campus Mitte, Department of Psychiatry and Psychotherapy

    Berlin, 10117

  • Central Institute of Mental Health (CIMH)

    Mannheim, 68159

Other trials in Germany

About this study

Official title: A Phase II Randomized, Double-blind, Active Placebo-controlled Parallel Group Trial to Examine the Efficacy and Safety of Psilocybin in Treatment-resistant Major Depression

The study aims to investigate the safety and efficacy of oral psilocybin administered under supportive conditions in treatment-resistant major depression (TRD).

The study is a bi-centric, prospective, randomized, active placebo-controlled study investigating the effects of 25 mg and 5 mg (p.o.) psilocybin versus placebo (100 mg nicotinamide) in a psychotherapeutic context in 144 patients with TRD from moderate to severe degree (ICD-10 F32/F33). After giving written informed consent and down-titration of their monoaminergic medication under supervision of the treating psychiatrist and the study team, patients will be randomly assigned to one of four trial arms using an online randomization tool: 1) receiving placebo (100 mg nicotinamide) at the first session and the full dose (25 mg) at the second; 2) receiving the presumably sub-effective dose (5 mg) at the first session and the full dose (25 mg) at the second; 3a) receiving the full dose (25 mg) at the first session and 5 mg at the second; 3b) receiving the full dose at both sessions. The two dosing sessions are accompanied by three preparatory and four integration sessions.

Drug administration must occur under psychotherapeutic conditions. Two trained therapists (one male, one female) will be assigned to each patient and be present during each dosing, preparatory and integration sessions. We will follow the safety guidelines provided by Johnson et al. (2), including a thorough preparation, establishment of trust/rapport, a safe and pleasing physical environment and sufficient interpersonal support. For safety reasons and close monitoring, patients will stay hospitalized for one night after each dosing session (i.e. in-patient setting).

Being tested
Psilocybin, Nicotinamide
Keywords
Psilocybin, Major depressive disorder, MDD, Psychedelics, 5-HT2A, double-blind
Medical subject headings
Depressive Disorder, Treatment-Resistant, Depressive Disorder, Major

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

Study groups in NCT04670081
Study groupRoleWhat they receive
NicotinamidePlacebo comparator1st dose: 100 mg Nicotinamide (Vitamin B3) - 2nd dose (after 6 weeks/after assessment of the primary endpoint): 25 mg Psilocybin
Receives: Drug: Psilocybin; Drug: Nicotinamide
Psilocybin (low-dose)Experimental1st dose: 5 mg Psilocybin - 2nd dose (after 6 weeks/after assessment of the primary endpoint): 25 mg Psilocybin
Receives: Drug: Psilocybin
Psilocybin (high-dose)Experimental1. 1st dose: 25 mg Psilocybin - 2nd dose (after 6 weeks/after assessment of the primary endpoint): 5 mg Psilocybin 2. 1st dose: 25 mg Psilocybin - 2nd dose (after 6 weeks/after assessment of the primary endpoint): 25 mg Psilocybin
Receives: Drug: Psilocybin

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Treatment Response (defined as a ≥ 50% drop in depressive symptom severity as measured by the Hamilton Rating Scale for Depression; HAM-D)

    The HAM-D is a 21-item rating scale to assess the severity of depressive symptoms after a semi-structured clinical interview. Items are rated on a scale from 0 (absent) to 4. The total score is calculated by summing the first 17 items (HAM-D17) and ranges between 0 and 51.

    Measured: Baseline - 6 weeks after the first dose

Secondary outcomes (4)

  1. % change in HAM-D total score

    Measured: Baseline - 1 day/1 week/6 weeks after the first dose

  2. Treatment Response (defined as a ≥ 50% drop in depressive symptom severity as measured by the Hamilton Rating Scale for Depression; HAM-D)

    Measured: Baseline - 1 day/1 week after the first dose

  3. Treatment response (≥ 50% drop) and % change in HAM-D total score

    Measured: Baseline - 12 weeks after the first dose

  4. Treatment response (≥ 50% drop) and % change in the Beck Depression Inventory (BDI) - II

    The BDI is a reliable and valid 21-item self-rating questionnaire for the assessment of depressive symptoms. Patients rate their symptoms according to four severity ratings per item (0-3). The total score determines the severity of depression, differentiating between absent (0 - 9), mild (10 - 18), moderate (19 - 29) and severe (≥ 30) depression.

    Measured: Baseline - 1 day/1 week/6 weeks after both doses

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted17 Dec 2020
  2. Study start10 Jun 2021
  3. Primary completion27 Feb 2024
  4. Study completion11 Dec 2024

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Masking
Triple blind
Who is masked
Participant, Care provider, Outcomes assessor
Enrolment
144 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT04670081
Sponsor's protocol ID
EPIsoDE_01
Acronym
EPIsoDE
Status last verified
Jan 2025
First submitted
9 Dec 2020
Last updated
20 Jan 2025
Results posted
No
Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
Yes

Publications

  • Mertens LJ, Koslowski M, Betzler F, Brand M, Evens R, Kartner L, Jungaberle A, Jungaberle H, Majic T, Schmitz CN, Strohle A, Scharf D, Spangemacher M, Wolff M, Assadi Z, Bahri S, Becher L, Farber LV, Kirchen N, Kulakova E, Kunz L, Meijer A, Rohrmoser B, Wellek S, Berger MM, Grunder G. Efficacy and Safety of Psilocybin in Treatment-Resistant Major Depression: The EPISODE Randomized Clinical Trial. JAMA Psychiatry. 2026 May 1;83(5):448-460. doi: 10.1001/jamapsychiatry.2026.0132.

    PubMed 41848690

Questions about this trial

What is this clinical trial studying?

A Phase 2 study testing Psilocybin and Nicotinamide in people with Treatment-resistant Depression, run by Central Institute of Mental Health, Mannheim at 2 sites in Germany.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 12 inclusion and 26 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 20 Jan 2025. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 2 sites in Germany. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Treatment Response (defined as a ≥ 50% drop in depressive symptom severity as measured by the Hamilton Rating Scale for Depression; HAM-D) (time frame: Baseline - 6 weeks after the first dose). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT04670081, which also lists 1 linked publication.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 20 Jan 2025.

AzTrials uses cookies for analytics and advertising. You can accept or reject them; the site works either way. Privacy Policy.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in